Srs Capital Advisors, Inc. Eliem Therapeutics, Inc. Transaction History
Srs Capital Advisors, Inc.
- $8.6 Billion
- Q3 2025
A detailed history of Srs Capital Advisors, Inc. transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 53 shares of ELYM stock, worth $217. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53Holding current value
$217% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ELYM
# of Institutions
67Shares Held
44.3MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.32MShares$5.41 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.3MShares$5.34 Million0.62% of portfolio
-
Kynam Capital Management, LP Princeton, NJ1.03MShares$4.23 Million0.36% of portfolio
-
Tang Capital Management LLC San Diego, CA1MShares$4.11 Million0.19% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...